Condition: Rheumatoid Arthritis (RA) · Hidradenitis Suppurativa (HS) · Sponsor: Sonoma Biotherapeutics, Inc.
To assess the emergence, type, severity, and potential causality of delayed adverse events following administration of a gene-modified Treg therapeutic.
This description comes directly from the study's public registry record.
Sabrina Fox-Bosetti, MPH · 415-992-6245 · clinicaloperations@sonomabio.com
Jason Do · 415-992-6245 · clinicaloperations@sonomabio.com
Always discuss trial participation with your own doctor first.
| UCSF Medical Center | San Francisco, California, United States | Recruiting |
| Stanford Medical Center | Stanford, California, United States | Recruiting |
| University of Colorado | Aurora, Colorado, United States | Recruiting |
| Northwestern University | Chicago, Illinois, United States | Recruiting |
| Tufts University | Boston, Massachusetts, United States | Recruiting |
| Massachusetts General Hospital | Boston, Massachusetts, United States | Recruiting |
| Brigham and Women's Hospital | Boston, Massachusetts, United States | Recruiting |
| University of Minnesota | Minneapolis, Minnesota, United States | Not Yet Recruiting |
| Duke University | Durham, North Carolina, United States | Not Yet Recruiting |
| The University of Texas MD Anderson Cancer Center | Houston, Texas, United States | Not Yet Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07123038